Nordea Investment Management AB Has $125.13 Million Position in Insulet Corporation $PODD

Nordea Investment Management AB raised its holdings in Insulet Corporation (NASDAQ:PODD) by 4.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 408,211 shares of the medical instruments supplier’s stock after buying an additional 18,553 shares during the quarter. Nordea Investment Management AB owned 0.58% of Insulet worth $125,125,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PODD. NewEdge Advisors LLC lifted its stake in Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the period. Strs Ohio acquired a new position in shares of Insulet in the 1st quarter worth approximately $1,004,000. Czech National Bank lifted its position in shares of Insulet by 6.8% during the 2nd quarter. Czech National Bank now owns 17,202 shares of the medical instruments supplier’s stock worth $5,405,000 after buying an additional 1,091 shares during the period. Financiere des Professionnels Fonds d investissement inc. acquired a new stake in Insulet in the 2nd quarter valued at $543,000. Finally, Aaron Wealth Advisors LLC acquired a new stake in Insulet in the 2nd quarter valued at $291,000.

Insulet Price Performance

PODD opened at $278.17 on Wednesday. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The company’s 50 day simple moving average is $305.30 and its 200-day simple moving average is $311.37. The stock has a market capitalization of $19.57 billion, a P/E ratio of 80.63, a price-to-earnings-growth ratio of 1.55 and a beta of 1.40.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. Insulet’s revenue was up 29.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.08 EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the subject of a number of analyst reports. Wells Fargo & Company lifted their price objective on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Wolfe Research increased their target price on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Evercore ISI started coverage on shares of Insulet in a research report on Tuesday, December 16th. They issued an “outperform” rating and a $370.00 price target on the stock. Canaccord Genuity Group raised their price objective on shares of Insulet from $432.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Royal Bank Of Canada lifted their target price on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Twenty-one equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $379.10.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.